The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Cellular Classification of Adult Non-Hodgkin Lymphoma

Added text to state that prognostic factors associated with symptoms requiring therapy include age 70 or older, beta-2-microglobulin of 3 mg/dL or more, and increased serum lactate dehydrogenase (cited Dhodapkar et al. as reference 36).

Added Treon et al. as reference 39.

Added Martin et al. as reference 49.

Revised text to state that alkylating agents or purine nucleoside analogs can predispose patients to myelodysplasia or acute leukemia (cited Leleu et al. as reference 50).

Added Fu et al. as reference 109.

Added Le Gouill et al. as reference 144.

Added Shimada et al. as reference 175.

Added Herrmann et al. as reference 209.

Added Geisler et al. as reference 226.

Treatment Option Overview

Revised text to state that for as many as 3 decades after diagnosis, patients are at a significantly elevated risk for second primary cancers (cited Hemminki et al. as reference 5).

Added Senff et al. as reference 51.

Aggressive, Stage I and Contiguous Stage II Adult Non-Hodgkin Lymphoma

Added Persky et al. as reference 6 and level of evidence 3iiiDiii.

Added text to state that a preliminary study using CHOP with or without etoposide for patients older than 60 years suggested improvement in EFS and OS for treatment delivered every 2 weeks versus the standard 3-week regimen (cited 2004 Pfreundschuh et al. as reference 7).

Added text on the RICOVER-60 study (cited 2008 Pfreundschuh et al. as reference 8 and level of evidence 1iiA).

Indolent, Noncontiguous Stage II/III/IV Adult Non-Hodgkin Lymphoma

Added Marcus et al. as reference 21.

Added bendamustine as a standard treatment option/oral alkylating agent (with or without steroids) (cited Robinson et al. as reference 44).

Added Morschhauser et al. as reference 53.

Added Gyan et al. as reference 64.

Aggressive, Noncontiguous Stage II/III/IV Adult Non-Hodgkin Lymphoma

Added text to state that a preliminary study using CHOP with or without etoposide for patients older than 60 years suggested improvement in EFS and OS for treatment delivered every 2 weeks versus the standard 3-week regimen (cited 2004 Pfreundschuh et al. as reference 12).

Added text on the RICOVER-60 study (cited 2008 Pfreundschuh et al. as reference 13 and level of evidence 1iiA).

Indolent, Recurrent Adult Non-Hodgkin Lymphoma

Added Khouri et al. as reference 25 and Sebban et al. as reference 26.

Aggressive, Recurrent Adult Non-Hodgkin Lymphoma

Added Vellenga et al. as reference 8.

Added Rezvani et al. as reference 15.

Back to Top

< Previous Section  |  Next Section >